BofA Securities analyst Alec Stranahan maintains $Recursion Pharmaceuticals (RXRX.US)$ with a hold rating, and adjusts the target price from $12 to $10.
According to TipRanks data, the analyst has a success rate of 42.3% and a total average return of -7.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Recursion Pharmaceuticals (RXRX.US)$'s main analysts recently are as follows:
While political and rate uncertainties persist as concerns, the overall condition of the Biopharma sector is seen as greatly enhanced from its lows in 2022. Among the stocks evaluated, preference is given to those in later-stage clinical trials or early launch phases; however, there's a growing investor interest in Phase 1 clinical programs that present near-term catalysts and data which reduce risks.
Healthcare technology stocks were generally under pressure for most of last year but witnessed a recovery in the last two months following the election. Coupled with cuts to consensus estimates since mid-last year, there appears to be attractive buying opportunities in the sector for 2025. Analysts believe that companies with robust balance sheets and consistent free cash flow profiles will face less risk of multiple contraction, despite potentially modest growth trends. On the contrary, the greatest risk is perceived for companies that have strained balance sheets and limited profitability prospects in both the near and longer term.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Alec Stranahan維持$Recursion Pharmaceuticals (RXRX.US)$持有評級，並將目標價從12美元下調至10美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.3%，總平均回報率為-7.1%。
此外，綜合報道，$Recursion Pharmaceuticals (RXRX.US)$近期主要分析師觀點如下：
儘管政治和利率的不確定性仍然令人擔憂，但生物製藥行業的整體狀況被認爲已從2022年的低點大幅改善。在評估的股票中，優先考慮處於後期臨牀試驗或早期啓動階段的股票；但是，投資者對提供短期催化劑和數據以降低風險的1期臨牀項目的興趣與日俱增。
在去年的大部分時間裏，醫療保健科技股普遍承壓，但在大選後的最後兩個月中出現了復甦。再加上自去年年中以來對共識預期的下調，該行業在2025年似乎有吸引力的買入機會。分析師認爲，儘管增長趨勢可能不大，但擁有強勁資產負債表和穩定的自由現金流狀況的公司面臨的多重收縮風險將降低。相反，對於資產負債表緊張且短期和長期盈利前景有限的公司來說，風險最大。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
